DE1620450C3 - 1 - (2-Hydroxybenzyl) -2-piperazinomethylbenzimidazoles, processes for their preparation and pharmaceuticals containing them - Google Patents

1 - (2-Hydroxybenzyl) -2-piperazinomethylbenzimidazoles, processes for their preparation and pharmaceuticals containing them

Info

Publication number
DE1620450C3
DE1620450C3 DE1620450A DE1620450A DE1620450C3 DE 1620450 C3 DE1620450 C3 DE 1620450C3 DE 1620450 A DE1620450 A DE 1620450A DE 1620450 A DE1620450 A DE 1620450A DE 1620450 C3 DE1620450 C3 DE 1620450C3
Authority
DE
Germany
Prior art keywords
hydroxybenzyl
preparation
benzimidazole
piperazinomethylbenzimidazoles
processes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE1620450A
Other languages
German (de)
Other versions
DE1620450B2 (en
DE1620450A1 (en
Inventor
Reinhard Dr. Hempel
Hans Dr.Phil. 7770 Ueberlingen Priewe
Dieter Dr. Rahtz
Helmer Dr. 2400 Luebeck Richter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of DE1620450A1 publication Critical patent/DE1620450A1/en
Publication of DE1620450B2 publication Critical patent/DE1620450B2/en
Application granted granted Critical
Publication of DE1620450C3 publication Critical patent/DE1620450C3/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/10—Radicals substituted by halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms

Description

'5'5

worin Y eine Methyl- oder 2-Hydroxyäthylgruppe darstellt, sowie deren Salze mit physiologisch verträglichen Säuren.wherein Y represents a methyl or 2-hydroxyethyl group, as well as their salts with physiologically compatible Acids.

2. Verfahren zur Herstellung von Verbindungen der allgemeinen Formel I, dadurch gekennzeichnet, daß man in an sich bekannter Weise N-(2-Hydroxybenzyl)-o-phenylendiamin mit Iminoäthern der allizemeinen Formel III2. Process for the preparation of compounds of the general formula I, characterized in that that in a known manner N- (2-hydroxybenzyl) -o-phenylenediamine with imino ethers the general formula III

NHNH

RO-C—CH,-HaloaenRO-C-CH, haloene

(III)(III)

worin R eine Alkylgruppe darstellt, oder deren Salze ringschließend kondensiert, worauf das I -(2 -Hydroxy benzyl)-2-halogenmethy I- benzimida/.ol mit einem Piperazin der allgemeinen Formel IVwherein R is an alkyl group, or the salts thereof are ring-closed, whereupon the I - (2-hydroxy benzyl) -2-halomethyl I-benzimida / .ol with a piperazine of the general formula IV

HNHN

N-YN-Y

(IV)(IV)

worin Y die oben angegebene Bedeutung hat, umgesetzt wird, und gegebenenfalls die erhaltenen Basen mit Säuren behandelt.in which Y has the meaning given above, is reacted, and optionally those obtained Bases treated with acids.

3. Arzneimittel, bestehend aus einer Verbindung gemäß Anspruch 1 und üblichen Zusatzstoffen.3. Medicament, consisting of a compound according to claim 1 and customary additives.

4545

Die Erfindung betrifft l-(2-Hydroxybenzyl)-2-pipcrazinomethyl-benzimidazole der allgemeinen Formel IThe invention relates to 1- (2-hydroxybenzyl) -2-pipcrazinomethyl-benzimidazoles of the general formula I.

(D(D

5555

N-YN-Y

worin Y eine Methyl- oder 2-Hydroxyäthylgruppe darstellt, sowie deren Salze mit physiologisch verträglichen Säuren.wherein Y represents a methyl or 2-hydroxyethyl group, as well as their salts with physiologically compatible Acids.

Ferner betrifft die Erfindung ein Verfahren zur Herstellung dieser Verbindungen. *The invention also relates to a process for the preparation of these compounds. *

Es wurde gefunden, daß die neuen Benzimidazole der allgemeinen Formel I sowie deren Salze eine überraschend hohe entzündungshemmende Wirksamkeit zeisien.It has been found that the new benzimidazoles of the general formula I and their salts are surprising show high anti-inflammatory effectiveness.

Als Säuren kommen sowohl organische Säuren, wie Zitronensäure, Weinsäure, Essigsäure, als auch anorganische Säuren wie Salzsäure in Betracht.The acids used are organic acids such as citric acid, tartaric acid, and acetic acid inorganic acids such as hydrochloric acid are suitable.

Zur Prüfung der neuen Verbindungen auf ihre entzündungshemmende Wirksamkeit wurde bei Ratten durch orale Eingabe die Hemmung des Kaolin-Ödems bestimmt (Literatur: J. Hillebrecht: Zur routinemäßigen Prüfung antiphlogistischer Substanzen im Rattenpfotentest, Arzneimittelforschung, 4 [1954], 607 bis 614).To test the new compounds for their anti-inflammatory properties Effectiveness was determined in rats by oral administration of the inhibition of kaolin edema (literature: J. Hillebrecht: Zur routinemäßigen Testing of anti-inflammatory substances in the rat paw test, Arzneimittelforschung, 4 [1954], 607 to 614).

Als Vergleichsbasis dient der therapeutische Index, gebildet aus der LD5,, und der ED40. Als Standard- und Vergleichssubstanz dient das wegen seiner entzündungshemmenden Eigenschaften bekannte 3.5-Dioxo-l,2-diphenyl-4-n-butyl-pyrazolidin. The therapeutic index, formed from the LD 5 ,, and the ED 40, serves as a basis for comparison. 3,5-Dioxo-1,2-diphenyl-4-n-butyl-pyrazolidine, which is known for its anti-inflammatory properties, is used as the standard and reference substance.

TabelleTabel

Substanzsubstance

3,5- Dioxo-1,2-diphenyl-3,5-dioxo-1,2-diphenyl-

4-n-butyl-pyrazolidin4-n-butyl-pyrazolidine

(Vergleichssubstanz)(Comparison substance)

l-(2-Hydroxybenzyl)-2-[4-(2-hydroxyäthyl)-
piperazinomethyl]-benzimidazol l- (2-hydroxybenzyl) -2- [4- (2-hydroxyethyl) -
piperazinomethyl] benzimidazole

l-(2-Hydroxybenzyl)-l- (2-hydroxybenzyl) -

2-(4-methyl-piperazino-2- (4-methyl-piperazino-

methyl)-benzimidazolmethyl) benzimidazole

LD51,LD 51 ,

Therapeutischer IndexTherapeutic index

270 4270 4

>2()00 IO> 2 () 00 IO

>564() 15-20> 564 () 15-20

Die Herstellung der neuen Benzimidazolderivate erfolgt in an sich bekannter Weise, indem man N-(2 - Hydroxybenzyl)-o-phenylendiamin der Formel IIThe preparation of the new benzimidazole derivatives takes place in a manner known per se by N- (2 - hydroxybenzyl) -o-phenylenediamine of the formula II

40 OH 40 OH

CH1 CH 1

NH1 NH 1

mit Irriinoäthern der allgemeinen Formel III
NHwith irriino ethers of the general formula III
NH

IlIl

RO-C-CH2-HaIOgCIiRO-C-CH 2 -HaIOgCIi

(III)(III)

worin R eine Alkylgruppe darstellt, oder deren Salze ringschließend kondensiert, worauf das l-(2-Hydroxybenzyl)-2- halogenmethyl - benzimidazol mit einem Piperazin der allgemeinen Formel IVwhere R is an alkyl group, or the salts thereof are ring-closed, whereupon the 1- (2-hydroxybenzyl) -2- halomethyl benzimidazole with a piperazine of the general formula IV

60 HN 60 HN

N-YN-Y

(IV)(IV)

worin Y die oben angegebene Bedeutung hat, umgesetzt wird, und gegebenenfalls die erhaltenen Basen mit Säuren behandelt.in which Y has the meaning given above, is reacted, and optionally the bases obtained treated with acids.

Das als Ausgangsmaterial benutzte N-(2-Hydroxybenzyl)-ο - phenylendiamin der Formel II vomThe N- (2-hydroxybenzyl) -ο used as starting material - Phenylenediamine of the formula II from

Schmelzpunkt 164 bis 166° C wird aus dem durch Kondensation von o-Phenylendiamin und Salicylaldehyd erhaltenen N-(2-Hydroxybenzal)-o-phenylendiamin durch Hydrieren mit Raney-Nickel in wasserfreiem Dioxan erhalten.
Die folgenden Beispiele erläutern die Erfindung.Melting point 164 to 166 ° C. is obtained from the N- (2-hydroxybenzal) -o-phenylenediamine obtained by condensation of o-phenylenediamine and salicylaldehyde by hydrogenation with Raney nickel in anhydrous dioxane.
The following examples illustrate the invention.

Beispiel 1example 1

89 g Chloressigsäureiminoätherhydrochlorid werden in 700 ml wasserfreiem Chloroform suspendiert. Die Suspension wird gerührt und mit Eis gekühlt. Portionsweise werden bei einer Maximaltemperatur von 10° C 120 g N-(2-Hydroxybenzyl)-o-phenylendiamin zugefügt. Nach beendeter Zugabe wird das Kühlbad entfernt und das Reaktionsgemisch erst eine halbe Stunde bei Raumtemperatur, dann 2 Stunden bei 40° C gerührt. Alsdann werden die farblosen Kristalle abgesaugt und mit Wasser gut gewaschen. Der Rückstand wird im Vakuum bei 40° C erst über Kaliumhydroxyd, dann über Phosphorpentoxyd getrocknet. 89 g of chloroacetic acid imino ether hydrochloride are suspended in 700 ml of anhydrous chloroform. The suspension is stirred and cooled with ice. Be portioned at a maximum temperature from 10 ° C. 120 g of N- (2-hydroxybenzyl) -o-phenylenediamine were added. When the addition is complete, the Removed cooling bath and the reaction mixture first half an hour at room temperature, then 2 hours stirred at 40 ° C. The colorless crystals are then filtered off with suction and washed well with water. The residue is dried in vacuo at 40 ° C. first over potassium hydroxide and then over phosphorus pentoxide.

Der Schmelzpunkt des 2-Chlormethyl-l-(2-hydroxybenzyl)-benzimidazols liegt bei 188°C. Ausbeute: 145 g.The melting point of 2-chloromethyl-1- (2-hydroxybenzyl) benzimidazole is 188 ° C. Yield: 145 g.

145 g 2-Chlormethyl-l-(2-hydroxybenzyl)-benzimidazol und 28,3 g Natriumcarbonat werden in 1200 ml 95%igem Äthanol suspendiert. Die Suspension wird mit Eis gekühlt. Unter Rühren werden 76 g N-(2-hydroxyäthyl)-piperazin zugetropft. Das Reaktionsgemisch wird noch 1 Stunde bei Raumtemperatur gerührt, anschließend wird es 5 Stunden unter Rückfluß gekocht. Nach Stehen über Nacht werden die Kristalle abgesaugt, mit Wasser durchgearbeitet, erneut abgesaugt, mit Wasser gewaschen und im Vakuum bei 60° C über Kaliumhydroxyd getrocknet.145 g of 2-chloromethyl-1- (2-hydroxybenzyl) benzimidazole and 28.3 g of sodium carbonate are suspended in 1200 ml of 95% ethanol. The suspension is cooled with ice. 76 g of N- (2-hydroxyethyl) piperazine are added dropwise with stirring. The reaction mixture is stirred for a further 1 hour at room temperature, then it is refluxed for 5 hours. After standing overnight the crystals are suctioned off, worked through with water, suctioned off again, washed with water and dried in vacuo at 60 ° C over potassium hydroxide.

Ausbeute: 165 g l-(2-Hydroxybenzyl)-2-[4-(2-hydroxyäthyl) - piperazinomethyl] - benzimidazol vom Schmelzpunkt 216 bis 218° C.Yield: 165 g of 1- (2-hydroxybenzyl) -2- [4- (2-hydroxyethyl) piperazinomethyl] benzimidazole vom Melting point 216 to 218 ° C.

Zu einer siedenden Lösung von 4,3 g Zitronensäure · H2O in 750 ml Äthanol werden unter RührenTo a boiling solution of 4.3 g of citric acid · H 2 O in 750 ml of ethanol are added with stirring

ίο 15g 1 - (2 - Hydroxybenzyl) - 2 - [4 - (2 - hydroxyäthyl)-piperazinomethyl]-benzimidazol portionsweise eingetragen. Die beim Abkühlen der klaren Lösung anfallenden Kristalle werden abgesaugt und bei 50° C im Vakuum bis zur Gewichtskonstanz getrocknet.ίο 15g 1 - (2 - hydroxybenzyl) - 2 - [4 - (2 - hydroxyethyl) piperazinomethyl] benzimidazole entered in portions. The crystals obtained on cooling the clear solution are filtered off with suction and im Vacuum dried to constant weight.

Man erhält 18,0 g l-(2-Hydroxybenzyl)-2-[4-(2-hydroxyäthyl) - piperazinomethyl] - benzimidazol - Citrat vom Schmelzpunkt 136° C (unter Zersetzung).18.0 g of 1- (2-hydroxybenzyl) -2- [4- (2-hydroxyethyl) are obtained - piperazinomethyl] - benzimidazole - citrate with a melting point of 136 ° C (with decomposition).

Beispiel 2Example 2

9,6 g 2-Chlormethyl -1-(2-hydroxybenzyl)-benzimidazol (hergestellt gemäß Beispiel 1) werden in 141 ml Äthanol suspendiert. Unter Rühren und Kühlen mit Eiswasser werden 8,5 g N-Methylpiperazin zugetropft. Das Reaktionsgemisch wird 2 Stunden bei Zimmertemperatur gerührt, anschließend wird es 2 Stunden unter Rückfluß erhitzt. Nach dem Erkalten werden die farblosen Kristalle abgesaugt, mit Äthanol gewaschen und bei 60°C im Vakuum getrocknet. 9.6 g of 2-chloromethyl -1- (2-hydroxybenzyl) benzimidazole (prepared according to Example 1) are suspended in 141 ml of ethanol. With stirring and cooling 8.5 g of N-methylpiperazine are added dropwise with ice water. The reaction mixture is 2 hours stirred at room temperature, then it is refluxed for 2 hours. After cooling down the colorless crystals are filtered off with suction, washed with ethanol and dried at 60 ° C in a vacuum.

Ausbeute: 7,5 g l-(2-Hydroxybenzyl)-2-(4-methylpiperazinomethyl)-benzimidazol vom Schmelzpunkt 246 bis 248° C.Yield: 7.5 g of 1- (2-hydroxybenzyl) -2- (4-methylpiperazinomethyl) benzimidazole from melting point 246 to 248 ° C.

Claims (1)

Patentansprüche:Patent claims: I. I -(2- Hydrojfybenzyl)- 2- piperazinomcthylbenzimidazole der allgemeinen Formel II. I - (2-Hydrojfybenzyl) -2-piperazinomethylbenzimidazole of the general formula I. OHOH (D(D CH1-N N-YCH 1 -N NY 1010
DE1620450A 1964-07-23 1965-06-10 1 - (2-Hydroxybenzyl) -2-piperazinomethylbenzimidazoles, processes for their preparation and pharmaceuticals containing them Expired DE1620450C3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DESC035513 1964-07-23
DESC037200 1965-06-10
DESC037199 1965-06-10

Publications (3)

Publication Number Publication Date
DE1620450A1 DE1620450A1 (en) 1970-02-19
DE1620450B2 DE1620450B2 (en) 1975-05-22
DE1620450C3 true DE1620450C3 (en) 1976-01-02

Family

ID=27212324

Family Applications (2)

Application Number Title Priority Date Filing Date
DE1620449A Expired DE1620449C3 (en) 1964-07-23 1965-06-10 Substituted benzimidazoles and processes for their preparation
DE1620450A Expired DE1620450C3 (en) 1964-07-23 1965-06-10 1 - (2-Hydroxybenzyl) -2-piperazinomethylbenzimidazoles, processes for their preparation and pharmaceuticals containing them

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE1620449A Expired DE1620449C3 (en) 1964-07-23 1965-06-10 Substituted benzimidazoles and processes for their preparation

Country Status (12)

Country Link
US (1) US3423413A (en)
BE (1) BE667333A (en)
BR (1) BR6571550D0 (en)
CH (1) CH494229A (en)
DE (2) DE1620449C3 (en)
DK (1) DK121376B (en)
ES (1) ES315729A1 (en)
GB (1) GB1115390A (en)
IL (1) IL24007A (en)
NL (1) NL143569B (en)
NO (1) NO122124B (en)
SE (1) SE339228B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3531485A (en) * 1967-08-14 1970-09-29 American Home Prod Aryl-substituted diazabicycloalkanes
DE2436883C2 (en) * 1974-07-29 1985-08-22 Schering AG, 1000 Berlin und 4709 Bergkamen Benzimidazole derivatives, processes for their preparation and pharmaceuticals containing them
US4404382A (en) * 1980-09-17 1983-09-13 The Upjohn Company Piperazinyl-substituted imidazoles
DE3132916A1 (en) * 1981-08-20 1983-03-03 Kali-Chemie Pharma Gmbh, 3000 Hannover 1-PHENYLINDAZOL-3-ON COMPOUNDS, METHODS AND INTERMEDIATE PRODUCTS FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
JPS5879983A (en) 1981-11-06 1983-05-13 Kanebo Ltd Novel benzimidazole derivative, its preparation and pharmaceutical composition thereof
JPS59199679A (en) * 1983-04-27 1984-11-12 Kanebo Ltd Novel benzimidazole derivative, its preparation and medicinal composition containing the same
GB8716313D0 (en) * 1987-07-10 1987-08-19 Janssen Pharmaceutica Nv 2-(heterocyclylalkyl)imidazopyridines
BR0114932A (en) * 2000-10-31 2004-01-06 Basf Drucksysteme Gmbh Use of hyperranified polyurethanes, printing ink, printing varnish, and use of printing varnishes
US6906075B2 (en) 2002-01-10 2005-06-14 Neurogen Corp. Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues
WO2003060475A2 (en) 2002-01-10 2003-07-24 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1h-benzoimidazole analogues
AR066165A1 (en) * 2007-09-18 2009-07-29 Univ Stanford METHODS OF TREATMENT OF A VIRAL INFECTION OF THE FAMILY FLAVIVIRIDAE, COMPOSITIONS FOR THE TREATMENT OF A VIRAL INFECTION OF THE FAMILY FLAVIVIRIDAE AND CONTROL TESTS TO IDENTIFY COMPOSITIONS FOR THE TREATMENT OF A VIRAL INFECTION OF THE FLAVIVIDA FAMILY
US9101628B2 (en) * 2007-09-18 2015-08-11 The Board Of Trustees Of The Leland Stanford Junior University Methods and composition of treating a flaviviridae family viral infection
US8940730B2 (en) 2007-09-18 2015-01-27 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions of treating a Flaviviridae family viral infection
US8975247B2 (en) * 2009-03-18 2015-03-10 The Board Of Trustees Of The Leland Stanford Junion University Methods and compositions of treating a flaviviridae family viral infection

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL302847A (en) * 1963-01-10

Also Published As

Publication number Publication date
DE1620449C3 (en) 1974-02-21
GB1115390A (en) 1968-05-29
DE1470319A1 (en) 1969-10-02
ES315729A1 (en) 1966-02-16
NL143569B (en) 1974-10-15
DE1620450B2 (en) 1975-05-22
NL6509573A (en) 1966-01-24
DE1620449B2 (en) 1973-07-26
DK121376B (en) 1971-10-11
IL24007A (en) 1969-06-25
BE667333A (en) 1966-01-24
DE1620449A1 (en) 1970-04-30
NO122124B (en) 1971-05-24
US3423413A (en) 1969-01-21
DE1470319B2 (en) 1975-09-18
SE339228B (en) 1971-10-04
BR6571550D0 (en) 1973-08-14
CH494229A (en) 1970-07-31
DE1620450A1 (en) 1970-02-19

Similar Documents

Publication Publication Date Title
DE1620450C3 (en) 1 - (2-Hydroxybenzyl) -2-piperazinomethylbenzimidazoles, processes for their preparation and pharmaceuticals containing them
DE1914999A1 (en) New guanylhydrazones and processes for their preparation
DE3336024A1 (en) 4-AMINO-L-BENZYL-PYRROLIDINONE AND ITS ACID ADDITION SALTS, METHOD FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS
EP0005828B1 (en) New substituted phenylpiperazine derivatives, pharmaceutical compositions containing them and process for their preparation
DE2818423A1 (en) NEW ISOCHINOLINE DERIVATIVES AND THE PROCESS FOR THEIR PRODUCTION
DE2712023A1 (en) SULFONAMIDOAMINOBENZOESIC ACID DERIVATIVES, MEDICINAL PRODUCTS CONTAINING SUCH, AND METHOD FOR MANUFACTURING THE SAME
EP0212481B1 (en) Indolinone derivatives, processes for their preparation, pharmaceutical compounds containing them and their use
DE3420193A1 (en) NEW SUBSTITUTED PYRROLIDINONES, METHOD FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS
DE1518452C3 (en) 4 substituted 2 benzhydryl 2 butanol derivatives and process for their preparation
EP0428939B1 (en) Cumarin derivatives, process for their preparation, their use and thiazolylacetic acid derivatives as intermediate
DE1695656C3 (en)
DE1103342B (en) Process for the preparation of new 1, 2-diphenyl-3, 5-dioxo-1, 2, 4-triazolidine derivatives
DE2463023C2 (en) S-Triazolo- [5,1-a] -isoquinoline derivatives, their salts and processes for their preparation
EP0004332A1 (en) Isoquinolines, process for their preparation, and pharmaceutical preparations containing them
EP0004529B1 (en) Tantomeric arylaminoimidazoline derivatives, their preparation and pharmaceutical formulations for analgetic application containing them
DE2124907A1 (en) 3 Amino 1,2,4 oxadiazoles, process for their preparation and medicinal preparations
DE2114884A1 (en) Basically substituted derivatives of 1 (2H) -phthalazinone
DE2059949A1 (en) Thienyl fatty acid derivatives, processes for their preparation and their use as pharmaceuticals
DE2164618A1 (en) Association with antihypertensive action and process for their preparation
CH529766A (en) Vasoactive and hypotensive dichlorophenoxy-ethyl-imidazolines - prepd. by reacting an aryloxy carboxylic acid with ethylene diamine or ammonia
DE2428193C2 (en) p- (4-Quinolylamino) benzamides, processes for their preparation and pharmaceutical preparations containing the same
DE3121137A1 (en) Novel pyridazino[4,5-b]indoles, processes for their preparation, their use and also pharmaceutical preparations based on these compounds, intermediates and their preparation
DE1018869B (en) Process for the preparation of aminoalkyl purine derivatives
DE1620128A1 (en) Process for the preparation of new organic amides
DE3151123A1 (en) 1,4-DISUBSTITUTED PIPERAZINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME

Legal Events

Date Code Title Description
C3 Grant after two publication steps (3rd publication)
E77 Valid patent as to the heymanns-index 1977
8330 Complete disclaimer